Literature DB >> 27568728

Lipid Management in a Japanese Community:Attainment Rate of Target Set by the Japan Atherosclerosis Society Guidelines for the Prevention of Atherosclerotic Cardiovascular Diseases 2012.

Hayato Tada1, Masa-Aki Kawashiri, Atsushi Nohara, Akihiro Inazu, Junji Kobayashi, Kenji Yasuda, Hiroshi Mabuchi, Masakazu Yamagishi, Kenshi Hayashi.   

Abstract

AIM: The Japan Atherosclerosis Society (JAS) guidelines for the prevention of atherosclerotic diseases 2012 (JAS2012) proposed lipid management targets; however, less data is available regarding the attainment rates of each target in community-based settings. Therefore, we assessed the attainment rates of lipid management targets among subjects who underwent Japanese specific health checkups.
METHODS: A total of 85,716 subjects (male=29,282, 34.2%) aged 40-74 years who underwent specific health checkups from 2012 to 2014 in Kanazawa city, Japan, were included in this study. We evaluated the attainment rates of the lipid management targets according to the JAS2012 guideline and investigated the clinical characteristics of the subjects without achieving the targets.
RESULTS: The target for LDL cholesterol (LDL-C) was the least attained in all risk categories, 89, 72, 50, and 34% for category I, II, III, and secondary prevention, respectively, in 2014. In addition, these rates inversely correlated with the grade of risk categories (p-value for trends <0.001). Attainment rate of the LDL-C target in the suspected chronic kidney disease (CKD) group was significantly lower than in the groups with diabetes, stroke, or absolute risk in category III (49.2, 60.3, 63.5, 54.4%, respectively, p-value <0.001 for each). Moreover, the attainment rate of the LDL-C target was significantly lower in subjects that did not receive lipid-lowering therapy than in those who received it in the secondary prevention (27.7 and 40.6%, respectively, p-value <0.001).
CONCLUSIONS: Lipid management is inadequate in community-based settings, particularly, in subjects with CKD and secondary prevention.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27568728      PMCID: PMC5383549          DOI: 10.5551/jat.36004

Source DB:  PubMed          Journal:  J Atheroscler Thromb        ISSN: 1340-3478            Impact factor:   4.928


  14 in total

1.  The relationship between serum total cholesterol and all-cause or cause-specific mortality in a 17.3-year study of a Japanese cohort.

Authors:  Tomonori Okamura; Hideo Tanaka; Naomi Miyamatsu; Takehito Hayakawa; Takashi Kadowaki; Yoshikuni Kita; Yasuyuki Nakamura; Akira Okayama; Hirotsugu Ueshima
Journal:  Atherosclerosis       Date:  2006-03-10       Impact factor: 5.162

2.  Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial.

Authors:  Haruo Nakamura; Kikuo Arakawa; Hiroshige Itakura; Akira Kitabatake; Yoshio Goto; Takayoshi Toyota; Noriaki Nakaya; Shoji Nishimoto; Masaharu Muranaka; Akira Yamamoto; Kyoichi Mizuno; Yasuo Ohashi
Journal:  Lancet       Date:  2006-09-30       Impact factor: 79.321

3.  Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis.

Authors:  Kunihiro Matsushita; Marije van der Velde; Brad C Astor; Mark Woodward; Andrew S Levey; Paul E de Jong; Josef Coresh; Ron T Gansevoort
Journal:  Lancet       Date:  2010-05-17       Impact factor: 79.321

Review 4.  Cross-sectional survey to assess the status of lipid management in high-risk patients with dyslipidemia: clinical impact of combination therapy with ezetimibe.

Authors:  Tamio Teramoto; Atsunori Kashiwagi; Shun Ishibashi; Hiroyuki Daida
Journal:  Curr Ther Res Clin Exp       Date:  2012-02

5.  Lipid and blood pressure control for the prevention of cardiovascular disease in hypertensive patients: a subanalysis of the OMEGA study.

Authors:  Tamio Teramoto; Ryuzo Kawamori; Shigeru Miyazaki; Satoshi Teramukai; Yuki Sato; Yasuyuki Okuda; Masayuki Shirayama
Journal:  J Atheroscler Thromb       Date:  2014-08-29       Impact factor: 4.928

6.  Executive summary of the Japan Atherosclerosis Society (JAS) guidelines for the diagnosis and prevention of atherosclerotic cardiovascular diseases in Japan -2012 version.

Authors:  Tamio Teramoto; Jun Sasaki; Shun Ishibashi; Sadatoshi Birou; Hiroyuki Daida; Seitaro Dohi; Genshi Egusa; Takafumi Hiro; Kazuhiko Hirobe; Mami Iida; Shinji Kihara; Makoto Kinoshita; Chizuko Maruyama; Takao Ohta; Tomonori Okamura; Shizuya Yamashita; Masayuki Yokode; Koutaro Yokote
Journal:  J Atheroscler Thromb       Date:  2013-05-11       Impact factor: 4.928

7.  Revised equations for estimated GFR from serum creatinine in Japan.

Authors:  Seiichi Matsuo; Enyu Imai; Masaru Horio; Yoshinari Yasuda; Kimio Tomita; Kosaku Nitta; Kunihiro Yamagata; Yasuhiko Tomino; Hitoshi Yokoyama; Akira Hishida
Journal:  Am J Kidney Dis       Date:  2009-04-01       Impact factor: 8.860

Review 8.  Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention.

Authors:  Mark J Sarnak; Andrew S Levey; Anton C Schoolwerth; Josef Coresh; Bruce Culleton; L Lee Hamm; Peter A McCullough; Bertram L Kasiske; Ellie Kelepouris; Michael J Klag; Patrick Parfrey; Marc Pfeffer; Leopoldo Raij; David J Spinosa; Peter W Wilson
Journal:  Circulation       Date:  2003-10-28       Impact factor: 29.690

9.  Association between combined lifestyle factors and non-restorative sleep in Japan: a cross-sectional study based on a Japanese health database.

Authors:  Minako Wakasugi; Junichiro James Kazama; Ichiei Narita; Kunitoshi Iseki; Toshiki Moriyama; Kunihiro Yamagata; Shouichi Fujimoto; Kazuhiko Tsuruya; Koichi Asahi; Tsuneo Konta; Kenjiro Kimura; Masahide Kondo; Issei Kurahashi; Yasuo Ohashi; Tsuyoshi Watanabe
Journal:  PLoS One       Date:  2014-09-30       Impact factor: 3.240

10.  Characterization of Autosomal Dominant Hypercholesterolemia Caused by PCSK9 Gain of Function Mutations and Its Specific Treatment With Alirocumab, a PCSK9 Monoclonal Antibody.

Authors:  Paul N Hopkins; Joep Defesche; Sigrid W Fouchier; Eric Bruckert; Gérald Luc; Bertrand Cariou; Barbara Sjouke; Trond P Leren; Mariko Harada-Shiba; Hiroshi Mabuchi; Jean-Pierre Rabès; Alain Carrié; Charles van Heyningen; Valérie Carreau; Michel Farnier; Yee P Teoh; Mafalda Bourbon; Masa-Aki Kawashiri; Atsushi Nohara; Handrean Soran; A David Marais; Hayato Tada; Marianne Abifadel; Catherine Boileau; Bernard Chanu; Shoji Katsuda; Ichiro Kishimoto; Gilles Lambert; Hisashi Makino; Yoshihiro Miyamoto; Matthieu Pichelin; Kunimasa Yagi; Masakazu Yamagishi; Yassine Zair; Scott Mellis; George D Yancopoulos; Neil Stahl; Johanna Mendoza; Yunling Du; Sara Hamon; Michel Krempf; Gary D Swergold
Journal:  Circ Cardiovasc Genet       Date:  2015-09-15
View more
  14 in total

Review 1.  Evidence-Based Carotid Interventions for Stroke Prevention: State-of-the-art Review.

Authors:  Dylan R Morris; Kengo Ayabe; Takashi Inoue; Nobuyuki Sakai; Richard Bulbulia; Alison Halliday; Shinya Goto
Journal:  J Atheroscler Thromb       Date:  2017-03-04       Impact factor: 4.928

2.  Pravastatin Reduces the Risk of Atherothrombotic Stroke when Administered within Six Months of an Initial Stroke Event.

Authors:  Naohisa Hosomi; Yoji Nagai; Kazuo Kitagawa; Yoko Nakagawa; Shiro Aoki; Tomohisa Nezu; Tatsuo Kagimura; Hirofumi Maruyama; Hideki Origasa; Kazuo Minematsu; Shinichiro Uchiyama; Masayasu Matsumoto
Journal:  J Atheroscler Thromb       Date:  2017-09-16       Impact factor: 4.928

3.  Profiles Combining Muscle Atrophy and Neutrophil-to-Lymphocyte Ratio Are Associated with Prognosis of Patients with Stage IV Gastric Cancer.

Authors:  Kota Shigeto; Takumi Kawaguchi; Shunji Koya; Keisuke Hirota; Toshimitsu Tanaka; Sachiko Nagasu; Masaru Fukahori; Tomoyuki Ushijima; Hiroo Matsuse; Keisuke Miwa; Koji Nagafuji; Takuji Torimura
Journal:  Nutrients       Date:  2020-06-24       Impact factor: 5.717

Review 4.  Low-Density Lipoprotein Cholesterol Level cannot be too Low: Considerations from Clinical Trials, Human Genetics, and Biology.

Authors:  Hayato Tada; Soichiro Usui; Kenji Sakata; Masayuki Takamura; Masa-Aki Kawashiri
Journal:  J Atheroscler Thromb       Date:  2020-04-30       Impact factor: 4.928

5.  The Association between Glomerular Filtration Rate Estimated on Admission and Acute Stroke Outcome: The Shiga Stroke Registry.

Authors:  Aryandhito Widhi Nugroho; Hisatomi Arima; Itsuko Miyazawa; Takako Fujii; Naomi Miyamatsu; Yoshihisa Sugimoto; Satoru Nagata; Masaru Komori; Naoyuki Takashima; Yoshikuni Kita; Katsuyuki Miura; Kazuhiko Nozaki
Journal:  J Atheroscler Thromb       Date:  2018-01-19       Impact factor: 4.928

6.  Statin Intolerance and Suboptimal Statin Therapy.

Authors:  Hayato Tada; Masa-Aki Kawashiri
Journal:  J Atheroscler Thromb       Date:  2018-11-22       Impact factor: 4.928

7.  The Relationship of Dietary Cholesterol with Serum Low-Density Lipoprotein Cholesterol and Confounding by Reverse Causality: The INTERLIPID Study.

Authors:  Yukiko Okami; Hirotsugu Ueshima; Yasuyuki Nakamura; Nagako Okuda; Hideaki Nakagawa; Kiyomi Sakata; Shigeyuki Saitoh; Akira Okayama; Katsushi Yoshita; Sohel R Choudhury; Queenie Chan; Paul Elliott; Jeremiah Stamler; Katsuyuki Miura
Journal:  J Atheroscler Thromb       Date:  2018-06-09       Impact factor: 4.928

8.  Cultural Barriers in the Treatment of Dyslipidemia: A Survey of Japanese Physician Attitudes.

Authors:  Shizuya Yamashita; Daisaku Masuda; Hidenori Arai; Yuji Matsuzawa
Journal:  J Atheroscler Thromb       Date:  2018-05-18       Impact factor: 4.928

9.  Association of proteinuria with incident atrial fibrillation in the general Japanese population.

Authors:  Yoshihiro Tanaka; Hayato Tada; Satoshi Hara; Kenshi Hayashi; Ravi B Patel; Tetsuo Nishikawa; Atsushi Hashiba; Masayuki Takamura; Philip Greenland; Masa-Aki Kawashiri
Journal:  J Cardiol       Date:  2020-08-23       Impact factor: 3.159

10.  Associations between questionnaires on lifestyle and atherosclerotic cardiovascular disease in a Japanese general population: A cross-sectional study.

Authors:  Hayato Tada; Masa-Aki Kawashiri; Kenji Yasuda; Masakazu Yamagishi
Journal:  PLoS One       Date:  2018-11-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.